A recent study showed that melanoma patients treated with anti-PD-1 antibodies presented an objective response rate (ORR) of 79% when baseline melanoma specimens had more than 20% of PD-1high/CTLA-4high CD8+ TILs while patients with fewer than 20% of PD- 1high/CTLA-4high CD8+ TILs were nonresponders [22]. This evidence concerns the gene CD8A and melanoma.